Guideline for radionuclide therapy in painful bone metastases;Leitlinie fur die radionuklidtherapie bei schmerzhaften knochenmetastasen

NuklearMedizin

Volumn 38, Issue 6 A, 1999, Pages 270-272

  Fischer, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETIDRONIC ACID RE 186; LEXIDRONAM SAMARIUM SM 153; RHENIUM 186; SAMARIUM 153; STRONTIUM 89; STRONTIUM CHLORIDE; RADIOPHARMACEUTICAL AGENT;

BONE METASTASIS; BONE SCINTISCANNING; CANCER LOCALIZATION; CANCER SCINTISCANNING; DIAGNOSTIC IMAGING; DOSIMETRY; HUMAN; PRACTICE GUIDELINE; RADIOBIOLOGY; REVIEW; ARTICLE; BONE TUMOR; HEALTH CARE QUALITY; METASTASIS; PAIN; PATHOPHYSIOLOGY; RADIOTHERAPY; STANDARD;

BONE NEOPLASMS; HUMANS; PAIN; PRACTICE GUIDELINES; QUALITY ASSURANCE, HEALTH CARE; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 0032589351     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Bayouth JE, Macey DJ, Kasi LP, Fosella FV. Dosimetry and toxicity of Samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35: 63-9.
2. Edwards GK, Santoro J, Taylor AT et al. Use of bone scintigraphy to select patients with multiple myeloma for treatment with strontium-89. J Nucl Med 1994; 35: 1992-4.
3. Herold TJ, Gross GP, Hung JC. A technique for measurement of strontium-89 in a dose calibrator. J Nucl Med Technol 1995; 23: 26-8.
4. Lewington VJ. Cancer therapy using bone-seeking isotopes. Phys Med Biol 1996; 41: 2027-42.
5. McEwan AJ, Amyotte GA, McGowan DG et al. A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-Cl) in patients with prostate cancer metastatic to bone. Nucl Med Commun 1994; 15: 499-504.
6. McEwan AJ, Porter AT, Venner PM et al. An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibod Immunoconj Radiopharm 1990; 3: 91-8.
7. Palmedo H, Bender H, Schomburg A et al. Schmerztherapie mit Rhenium-186 HEDP bei multiplen Knochenmetastasen. Nucl Med 1996; 35: 63-7.
8. Porter AT, McEwan AJ, Powe JE et a. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-13.
9. Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40.
10. Resche I, Chatal J.-F, Pecking A et al. A dose-controlled study of 153Sm-Ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful metastases. Eur J Cancer 1997; 33: 1583-91.
11. Robinson RG, Blake GM, Preston DF et al. Strontium-89 treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989; 9: 271-81.
12. Schoeneich G, Müller SC, Palmedo H. Indikation zur nuklearmedizinischen Therapie bei fortgeschrittenem Prostatakarzinom. Der Urologe 1998; 37: 162-6.
13. Serafini AN, Houston SJ, Resche I et al. Palliation of pain associated with metastatic bone cancer using Samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574-81.
14. Silberstein EB, Williams C. Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 1985; 26: 345-8.
15. Taylor AJ jr. Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med 1994; 35: 2054.